ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2021

Omega-3 Fatty Acids Are Associated with a Lower Prevalence of Autoantibody Positivity in HLA-DR Shared Epitope Positive Subjects Who Are at Increased Risk for Future RA

Ryan W. Gan1, M. Kristen Demoruelle2, Kevin D. Deane3, Michael H. Weisman4, Jane H. Buckner5, Peter K. Gregersen6, Ted R. Mikuls7, James R. O'Dell7, Richard M. Keating8, Tasha Fingerlin9, Gary O. Zerbe10, Michael J. Clare-Salzler11, V. Michael Holers12 and Jill M. Norris13, 1Colorado School of Public Health, University of Colorado Denver, Aurora, CO, 2Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3Division of Rheumatology, U Colo Denver, Aurora, CO, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Feinstein Insititute for Medical Research, Manhasset, NY, 7University of Nebraska Medical Center, Omaha, NE, 8Division of Rheumatology, Scripps Health, La Jolla, CA, 9National Jewish Health, Denver, CO, 10Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 11Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, 12Rheumatology Division, Univ of Colorado School of Med, Aurora, CO, 13University of Colorado Denver, Aurora, CO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, dietary supplements and epidemiologic methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Epidemiology and Public Health II: RA and Lifestyle Factors

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Studies of fish intake suggest that omega-3 fatty
acids (n-3 FAs) could be protective against the development of RA.  Previously, we found n-3 FAs were
inversely associated with anti-CCP2 positivity in subjects without RA, but at
risk for future RA (Gan 2015).  In
this present study, we investigated whether n-3 FAs were also associated with RF
positivity, and if the associations between n-3 FA and these autoantibodies
(Abs) differed by HLA shared epitope (SE) positivity, in subjects at risk for
future RA.

Methods: The
Studies of the Etiology of RA (SERA) cohort includes subjects who are RA-free
by 1987 ACR criteria, but who are at increased risk for future RA, based on
family history of RA. To examine the association between n-3 FA and Ab positivity, we utilized two approaches: 1) a nested
case-control study
to determine the
association between RF and anti-CCP2 positivity and percent of n-3 FA in
erythrocyte membranes (RBC n-3 FA%); 2) a cross-sectional study of
the baseline visit of the larger SERA cohort, in which we determined the association between n-3 FA
supplement use and RF and anti-CCP2 positivity. We assessed the role of SE as
an effect modifier using an interaction term in logistic regression models. As
significant n-3 FA*SE interactions were detected for RF, results were stratified
by SE status for both RF and anti-CCP2 for comparison.

Results: In the nested case-control study, increases in
several RBC n-3 FA%s were associated with a lower prevalence of RF and anti-CCP
positivity in SE positive subjects but not SE negative subjects (Table 1). In
the larger SERA cohort baseline analyses, n-3 FA supplement use was associated
with a lower prevalence of RF positivity in SE positive subjects, but not SE
negative subjects; similar trends were seen with anti-CCP2 positivity (Table 2).

Conclusion: We demonstrate
that n-3 FAs are inversely associated with RF positivity in SE positive subjects
with a familial risk of RA. In combination with our prior work that found n-3
FAs are inversely associated with anti-CCP2 positivity, these data suggests a potential
protective effect of n-3 FAs against broader RA-related autoimmunity. Furthermore,
the protective effect of n-3 FAs on RA-related autoimmunity may be most
pronounced in SE positive subjects. Our findings could be explained by the
ability of n-3 FAs to change the conformation of membrane MHC class II molecules
and alter antigen presentation and Ab generation (Hughes
1996, Rockett 2015), or other adaptive immune
mechanisms yet to be identified. This needs further investigation, as it could
lead to the use of n-3 FAs in the prevention of RA.

Table 1: Nested case-control study associations between increasing RBC n-3 FA% and the outcomes of anti-CCP2 and RF by shared epitope status (27 RF positive subjects, 40 anti-CCP2 positive subjects, and 69 antibody negative subjects).

RF

SE Positive

(n=11 RF pos.)

SE Negative

(n=16 RF pos.)

RBC n-3 FA%

OR*

95% CI

p

OR*

95% CI

p

pinter 

Total n-3 FA

0.27

0.10-0.79

0.02

0.94

0.49-1.78

0.84

0.04

ALA(18:3n-3)

1.02

0.54-1.93

0.94

1.21

0.59-2.48

0.60

0.73

EPA(20:5n-3)

0.43

0.10-1.82

0.25

0.98

0.55-1.75

0.95

0.28

DPA(22:5n-3)

0.39

0.17-0.89

0.03

0.74

0.35-1.56

0.42

0.26

DHA(22:6n-3)

0.34

0.13-0.91

0.03

1.02

0.52-1.98

0.96

0.06

EPA+DHA

0.31

0.10-0.91

0.03

0.99

0.53-1.87

0.98

0.06

Anti-CCP2

SE Positive

(n=24 Anti-CCP2 pos.)

SE Negative

(n=16 Anti-CCP2 pos.)

RBC n-3 FA%

OR*

95% CI

p

OR*

95% CI

p

pinter 

Total n-3 FA

0.42

0.20-0.89

0.03

0.74

0.39-1.40

0.35

0.24

ALA(18:3n-3)

0.90

0.24-1.50

0.68

0.68

0.27-1.71

0.41

0.60

EPA(20:5n-3)

0.27

0.09-0.83

0.02

0.61

0.32-1.17

0.14

0.20

DPA(22:5n-3)

0.84

0.47-1.52

0.56

0.92

0.46-1.83

0.80

0.85

DHA(22:6n-3)

0.47

0.24-0.92

0.03

0.79

0.42-1.51

0.48

0.25

EPA+DHA

0.40

0.18-0.85

0.02

0.73

0.39-1.37

0.33

0.20

*Adjusted for age at visit, sex, race, site, current smoker, and income. The odds ratios reported are for a standard deviation (SD) difference in n-3 FA %. SDs: Total n-3 FA = 1.8; ALA = 0.3; EPA = 0.6; DPA = 2.2; DHA = 3.5; EPA+DHA = 4.1.

 p-value for interaction, testing a difference in the effect of n-3 FA % in RBCs between SE positive and negative stratums.

Table 2: Cross-sectional study associations between self-reported n-3 FA supplement use and the outcomes of RF (n=115 subjects) and anti-CCP2 (n=44 subjects) positivity at baseline by SE status in 2,331 subjects at baseline.

RF  

SE Positive

(n=60 RF pos.)

SE Negative

(n=55 RF pos.)

n-3 FA Supplement

OR*

95% CI

p

OR*

95% CI

p

pinter 

Yes vs. No

0.35

0.15-0.82

0.02

1.21

0.64-2.28

0.56

0.02

Anti-CCP2

SE Positive

(n=27 Anti-CCP2 pos.)

SE Negative

(n=17 Anti-CCP2 pos.)

n-3 FA Supplement

OR*

95% CI

p

OR*

95% CI

p

pinter 

Yes vs. No

0.28

0.07-1.20

0.09

1.11

0.35-3.49

0.83

0.14

*Model includes interaction term between n-3 FA supplement use and SE, adjusted for age, sex, race, site, current smoking, and other supplement use. The RF outcome model excluded the 44 anti-CCP2 positive subjects from the analysis. The anti-CCP2 outcome model excluded the 115 RF positive subjects from the analysis.

 p-value for interaction, testing a difference in the effect of n-3 FA supplement use between SE positive and negative stratums.


Disclosure: R. W. Gan, None; M. K. Demoruelle, None; K. D. Deane, None; M. H. Weisman, None; J. H. Buckner, None; P. K. Gregersen, Illumina Inc., 1,Janssen Pharmaceutica Product, L.P., 5,Biogen, Idec, 5; T. R. Mikuls, None; J. R. O'Dell, None; R. M. Keating, None; T. Fingerlin, None; G. O. Zerbe, None; M. J. Clare-Salzler, None; V. M. Holers, Shared patent with Stanford University for use of biomarkers to predict clinical phenotypes in rheumatoid arthritis., 7; J. M. Norris, None.

To cite this abstract in AMA style:

Gan RW, Demoruelle MK, Deane KD, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, O'Dell JR, Keating RM, Fingerlin T, Zerbe GO, Clare-Salzler MJ, Holers VM, Norris JM. Omega-3 Fatty Acids Are Associated with a Lower Prevalence of Autoantibody Positivity in HLA-DR Shared Epitope Positive Subjects Who Are at Increased Risk for Future RA [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/omega-3-fatty-acids-are-associated-with-a-lower-prevalence-of-autoantibody-positivity-in-hla-dr-shared-epitope-positive-subjects-who-are-at-increased-risk-for-future-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/omega-3-fatty-acids-are-associated-with-a-lower-prevalence-of-autoantibody-positivity-in-hla-dr-shared-epitope-positive-subjects-who-are-at-increased-risk-for-future-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology